Perella Weinberg Partners

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Retrieved on: 
星期一, 五月 6, 2024
Research fellow, Metabolism, Economics, AstraZeneca, Biomedical sciences, Inflammation, Princeton University, GSK plc, Roche, Mount Sinai Hospital, Harvard Medical School, Form 6-K, Phi Beta Kappa, Therapy, Physician, Columbia University, IPO, Perella Weinberg Partners, Former, Wellesley College, Stanford University, Business development, Stem cell, Neoplasm, Columbia Business School, Pharmaceutical industry

The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Key Points: 
  • The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
  • "When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector.
  • Previously, Lauren co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully managed its merger with Perella Weinberg Partners.
  • Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

Perella Weinberg Reports First Quarter 2024 Results

Retrieved on: 
星期五, 五月 3, 2024
International, PWP, Domestic, Partnership, Webcast, Common stock, Perella Weinberg Partners, RSU, GAAP

NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (the “Firm” or “PWP”) (NASDAQ:PWP) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • GAAP total compensation and benefits were $115.4 million for the first quarter of 2024, compared to $117.6 million for the first quarter of 2023.
  • GAAP non-compensation expenses were $40.3 million for the first quarter of 2024, compared to $36.5 million for the first quarter of 2023.
  • Adjusted non-compensation expenses were $37.0 million for the first quarter of 2024, compared to $34.5 million for the same period a year ago.
  • Management will host a webcast and conference call on Friday, May 3, 2024 at 9:00 am ET to discuss Perella Weinberg’s financial results for the first quarter ended March 31, 2024.

Perella Weinberg to Announce First Quarter 2024 Financial Results and to Host Conference Call on May 3, 2024

Retrieved on: 
星期五, 四月 19, 2024
Perella Weinberg Partners, Domestic, International, PWP

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (“PWP”) (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial results for the first quarter 2024 on Friday, May 3, 2024, before the market opens.

Key Points: 
  • NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (“PWP”) (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial results for the first quarter 2024 on Friday, May 3, 2024, before the market opens.
  • Management will host a conference call and webcast to review PWP’s results on the same day at 9:00AM ET.
  • A webcast of the conference call will be available to the public on a listen-only basis and can be accessed through the Investors section of PWP's website at https://investors.pwpartners.com .
  • The conference call can also be accessed by the following dial-in information:
    A replay of the call will also be available two hours after the live call through May 10, 2024.

Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million

Retrieved on: 
星期四, 四月 25, 2024
Sale, Consumer, Exercise, Morgan Stanley, Patient, Perella Weinberg Partners, Earnout

DUBLIN, April 25, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by ESTEVE and enter into a definitive agreement with ESTEVE for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.

Key Points: 
  • ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
  • Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by ESTEVE and enter into a definitive agreement with ESTEVE for the sale of the Rare Diseases business.
  • "Divesting the HRA Pharma Rare Diseases business further supports our position as a leading fast-moving consumer goods company," said Patrick Lockwood-Taylor, Perrigo President and Chief Executive Officer.
  • We thank all HRA Rare Diseases colleagues for their dedication and wish them all the best on continuing to improve the lives of patients with rare diseases."

David Higley Joins Perella Weinberg as Partner

Retrieved on: 
星期二, 四月 2, 2024
Perella Weinberg Partners, University, BBA, Partner, Interactive media, JD, Financial services

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, announced today that David Higley has joined the Firm as a Partner in the Advisory Business.

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, announced today that David Higley has joined the Firm as a Partner in the Advisory Business.
  • Based in Los Angeles, Mr. Higley will enhance the Firm’s Global Media & Technology practice providing strategic advice to clients globally in the media and interactive entertainment sectors.
  • Mr. Higley joins Perella Weinberg from Lazard, where he served as a Managing Director and the Global Head of the Interactive Media and Technologies Group, advising clients on mergers and acquisitions, capital raising and strategic advisory.
  • He brings a depth of experience and a breadth of relationships in an active and growing segment of the market,” said Andrew Bednar, Chief Executive Officer of Perella Weinberg.

Cerity Partners Announces Combination with Agility to Offer Outsourced Chief Investment Officer Capability

Retrieved on: 
星期一, 四月 8, 2024
Element, CIO, Organization, Growth, Partnership, Research, Perella Weinberg Partners, UHNW, Willkie Farr & Gallagher, Management

NEW YORK, April 8, 2024 /PRNewswire/ -- Cerity Partners, a leading independent wealth management firm in the U.S., announced today that it is combining with Denver-based Agility, a provider of outsourced chief investment officer ("OCIO") solutions for endowments, foundations, family offices, corporations, healthcare organizations, and other clientele. Upon closing, Agility will form Cerity Partners OCIO.

Key Points: 
  • The addition of Denver-based Agility will expand Cerity Partners' capabilities through outsourced chief investment officer services to non-profit organizations, UHNW individuals, and family offices.
  • NEW YORK, April 8, 2024 /PRNewswire/ -- Cerity Partners, a leading independent wealth management firm in the U.S., announced today that it is combining with Denver-based Agility, a provider of outsourced chief investment officer ("OCIO") solutions for endowments, foundations, family offices, corporations, healthcare organizations, and other clientele.
  • Agility's investment team will establish an OCIO investment committee within Cerity Partners.
  • Broadhaven Capital Partners served as financial advisor and Willkie Farr & Gallagher LLP served as legal advisor to Cerity Partners.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
星期五, 四月 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Retrieved on: 
星期一, 四月 1, 2024
Health, Neurology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SVB Securities, Bankruptcy, Neurotoxin, Multiple sclerosis, Patient, King & Spalding, Merz, Sale, Perella Weinberg Partners, LLP, Security (finance), United States bankruptcy court, Morgan Stanley, Ernst & Young, DSM-IV codes, Therapy, Acorda Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
  • Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany.
  • The decision to file for Chapter 11 protection follows a lengthy strategic review during which the Company explored a wide range of strategic options.
  • Upon court approval, Acorda expects to minimize the impact of the bankruptcy process on its employees, customers, patients, and other key stakeholders.

Bridger Aerospace Strengthens Board with the Addition of Seasoned Business Leaders Elizabeth C. Fascitelli and David A. Schellenberg as Independent Directors

Retrieved on: 
星期五, 三月 8, 2024
Chartered, Goldman Sachs, Conair Group, Jim Pattison Group, Bridger Aerospace, Principal, Dartmouth College, Risk management, Aviation, Growth, Cold, CHDI, Perella Weinberg Partners, Risk, Young, FCA, University, Partner, Business administration, Cascade Aerospace, Harvard Business School, FCPA, Corporation, Woman, Management

Jeffrey Kelter, Bridger’s Chairman, commented, “The addition of two proven leaders is a very powerful statement in Bridger’s continuing evolution as a public company.

Key Points: 
  • Jeffrey Kelter, Bridger’s Chairman, commented, “The addition of two proven leaders is a very powerful statement in Bridger’s continuing evolution as a public company.
  • Additionally, Mr. Schellenberg added that "I am honored to join the Board at such an exciting time for Bridger.
  • Ms. Fascitelli earned a Bachelor of Arts from Dartmouth College and a Master’s in Business Administration from Harvard Business School.
  • David A. Schellenberg, age 60, is a seasoned businessman with over 30 years of operating and financial leadership and risk management experience.

Viper Energy Announces Pricing of Secondary Common Stock Offering by Diamondback Energy, Inc.

Retrieved on: 
星期三, 三月 6, 2024
Attention, Goldman Sachs, J.P. Morgan & Co., TPH, Telephone, Scotiabank, Sale, Perella Weinberg Partners, Equity capital markets, Form, Broadridge Financial Solutions, BofA Securities, Roth Capital Partners, Security (finance), Evercore, Barclays, Form S-3

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).

Key Points: 
  • MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).
  • The Secondary Offering is expected to close on March 8, 2024, subject to customary closing conditions.
  • J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.
  • The Secondary Offering may only be made by means of a prospectus supplement and related base prospectus.